Sustained impact of real-time continuous glucose monitoring in adults with type 1 diabetes on insulin pump therapy: Results after 24 months RESCUE study
posted on 2020-10-19, 08:54authored bySara Charleer, Christophe De Block, Frank Nobels, Régis P. Radermecker, Ine Lowyck, Annelies Mullens, Denis Scarnière, Katrien Spincemaille, Marie Strivay, Eric Weber, Youri Taes, Chris Vercammen, Bart Keymeulen, Chantal Mathieu, Pieter Gillard, the RESCUE trial investigators
<b>Objective:</b>
In recent years, a growing number of people with type 1 diabetes have access to
real-time continuous glucose monitoring (rtCGM). Long-term benefits of rtCGM
are unclear due to lack of large studies of long duration. We evaluated whether
real-world rtCGM-use up to 24 months offered benefits, in particular to those
living with impaired awareness of hypoglycemia (IAH).
<p><b>Research Design and
Methods:</b> This 24-month, prospective, observational, cohort
study followed 441<b> </b>adults with
insulin pumps receiving full reimbursement for rtCGM. Forty-two percent had IAH.
Primary endpoint was evolution of HbA<sub>1c</sub>, with secondary endpoints
change in acute hypoglycemia complications, diabetes-related work absenteeism,
and quality of life (QOL) scores. Additionally, we evaluated if people could
achieve glycemic consensus targets during follow-up.</p>
<p><b>Results:</b>
After 24 months, HbA<sub>1c</sub> remained significantly lower compared to
baseline (7.64% [60 mmol/mol] vs 7.37% [57 mmol/mol], p<0.0001). Sustained benefits
were also observed for the score on the hypoglycemia fear survey and hypoglycemia-related
acute complications irrespective of hypoglycemia awareness level. People with IAH
had the strongest improvement, especially for severe hypoglycemia (862 events
year before vs 119 events per 100 patient-years in second year, p<0.0001).
Over 24 months, more people were able to meet hypoglycemia consensus targets at
the expense of slightly less people achieving hyperglycemia consensus targets.
Furthermore, the number of people with HbA<sub>1c</sub> <7% (<53
mmol/mol) without severe hypoglycemia events more than doubled (11.0% vs 25.4%,
p<0.0001).</p>
<p><b>Conclusion:</b>
Use of rtCGM led to sustained improvements in hypoglycemia-related glucose
control over 24 months. Lower fear of hypoglycemia, less acute hypoglycemia-related
events and diabetes-related days off work were observed, particularly in those with
IAH.</p>
Funding
No funding was available. S.C. received a doctoral grant strategic basic research and P.G. received a grant for a clinical PhD fellowship from FWO (Fonds Wetenschappelijk Onderzoek).